Aby J. Mathew Sells 637 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 637 shares of the firm’s stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $23.70, for a total transaction of $15,096.90. Following the completion of the sale, the executive vice president now owns 353,118 shares of the company’s stock, valued at approximately $8,368,896.60. The trade was a 0.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BioLife Solutions Price Performance

BLFS stock opened at $22.03 on Friday. The firm has a 50 day moving average of $22.72 and a 200-day moving average of $24.97. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -20.78 and a beta of 1.82. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12-month low of $18.70 and a 12-month high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. The firm had revenue of $23.94 million during the quarter, compared to the consensus estimate of $22.22 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. As a group, equities analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. increased its holdings in BioLife Solutions by 28.1% during the 4th quarter. Principal Financial Group Inc. now owns 244,247 shares of the medical equipment provider’s stock valued at $6,341,000 after acquiring an additional 53,532 shares in the last quarter. D.A. Davidson & CO. grew its position in shares of BioLife Solutions by 1.3% in the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock valued at $1,069,000 after purchasing an additional 519 shares during the last quarter. Peregrine Capital Management LLC grew its position in shares of BioLife Solutions by 18.1% in the fourth quarter. Peregrine Capital Management LLC now owns 352,205 shares of the medical equipment provider’s stock valued at $9,143,000 after purchasing an additional 54,100 shares during the last quarter. New York State Common Retirement Fund increased its stake in shares of BioLife Solutions by 4.3% during the 4th quarter. New York State Common Retirement Fund now owns 260,315 shares of the medical equipment provider’s stock worth $6,758,000 after purchasing an additional 10,836 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in shares of BioLife Solutions during the 4th quarter worth approximately $638,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

BLFS has been the subject of a number of analyst reports. Wall Street Zen downgraded BioLife Solutions from a “hold” rating to a “sell” rating in a research note on Wednesday, May 21st. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Tuesday, May 13th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $31.17.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.